en Vaccine development, efficacy and safety evaluation Vaccine development, efficacy and safety evaluation Review article Review article <span style="font-size:10pt"><span style="tab-stops:62.4pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.1pt">Rabies is a zoonotic disease, endemic mostly in Asia and Africa. Rabies virus belongs to the family <i>Rhabdoviridae</i>, genus <i>Lyssavirus</i>. Because infection with rabies virus has no cure and is life-threatening, vaccination is an important preventive measure to combat this disease in humans and animals. On the other hand, considering the limited availability of rabies vaccines in some of less developed countries with a higher rate of human rabies death each year, the need for an alternative strategy to produce a cost-effective and immunogenic vaccine against this disease is essential. In this review, we provide a brief overview of rabies vaccine development and its recent basic research. We also describe how viral vectors such as poxvirus vector, adenovirus replicons, and reverse genetics are manipulated for efficient novel formulated vaccines against this infection and we highlight possible future developments</span></span></span></span> Rabies, Rabies Vaccines, Vaccine development, Reverse genetics 39 44 http://vacres.pasteur.ac.ir/browse.php?a_code=A-10-7881-1&slc_lang=en&sid=1 Mehdi Rahpeyma mmeh10@yahoo.com 0000-0003-4989-8977 Yes Rabies National Reference laboratories & WHO collaborative centers, Department of Virology, Pasteur Institute of Iran, Tehran, Iran. Mohammad Sadeq Khosravy mskhosravy@gmail.com No DVM, Researcher, WHO Collaborating Center for Reference and Research on Rabies, Department of Virology, Pasteur Institute of Iran, Tehran, Iran